Daily Cosmetic Research Analysis
Three studies shape cosmetic and aesthetic care today: a prospective oncoplastic surgery series shows that intraoperative ultrasound combined with chest wall perforator flaps can expand breast-conserving indications while maintaining favorable cosmetic results; an evaluator-blinded randomized trial finds pure PDGF improves outcomes after RF microneedling; and an ion-paired tranexamic acid–mandelic acid complex enhances skin permeation and reduces pigmentation versus TXA alone.
Summary
Three studies shape cosmetic and aesthetic care today: a prospective oncoplastic surgery series shows that intraoperative ultrasound combined with chest wall perforator flaps can expand breast-conserving indications while maintaining favorable cosmetic results; an evaluator-blinded randomized trial finds pure PDGF improves outcomes after RF microneedling; and an ion-paired tranexamic acid–mandelic acid complex enhances skin permeation and reduces pigmentation versus TXA alone.
Research Themes
- Oncoplastic breast-conserving surgery with enhanced cosmesis
- Growth factor adjuncts to improve aesthetic procedure outcomes
- Formulation engineering to boost depigmenting agent delivery
Selected Articles
1. The Combination of Chest Wall Perforator Flaps and Surgeon-Performed Breast Ultrasound: An Effective Synergy to Expand the Boundaries of Breast-Conserving Surgery.
In a prospective single-institution series of 73 women with stage 0–III breast cancer and high resection-to-breast volume ratios, intraoperative ultrasound-guided excision combined with chest wall perforator flap reconstruction achieved favorable surgical, cosmetic, and short-term oncologic outcomes. The approach helped avoid mastectomy, particularly in small-to-medium breasts with unfavorable ARR.
Impact: This oncoplastic strategy expands eligibility for breast-conserving surgery while maintaining aesthetic outcomes, addressing a major clinical and cosmetic need.
Clinical Implications: Combine IOUS with CWPFs to enable wider adoption of breast conservation in patients with high ARR, especially those with small-to-medium breasts; implement multidisciplinary planning, surgeon-performed ultrasound, and tailored perforator flap selection to optimize margins and cosmetic symmetry.
Key Findings
- Prospective series of 73 patients (median age 57 years; median tumor size 32 mm) undergoing IOUS + CWPF reconstruction.
- High anatomical complexity: 43.8% multifocal/multicentric lesions; median ARR 30.2%.
- Multiple perforator flap types used (LiCAP 53.4%, MICAP 19.2%, LTAP 16.4%, AICAP 8.2%, TDAP 2.7%) with favorable surgical, cosmetic, and short-term oncologic outcomes.
- Approach effectively avoided mastectomy in patients otherwise ineligible for breast conservation.
Methodological Strengths
- Prospective, consecutive cohort with standardized oncoplastic workflow.
- Real-time intraoperative ultrasound guidance paired with tailored perforator flap reconstruction.
Limitations
- Single-center, nonrandomized design without a control comparator.
- Short-term oncologic follow-up; detailed margin status and patient-reported outcomes not reported in the abstract.
Future Directions: Conduct multicenter controlled trials comparing IOUS + CWPFs versus standard BCS or alternative oncoplastic approaches, with long-term local control, patient-reported outcomes, and cost-effectiveness.
BACKGROUND: Intraoperative ultrasound-guided breast-conserving surgery (IOUS) combined with chest wall perforator flaps (CWPFs) is a promising approach to avoid mastectomy, especially for patients with high anticipated resection-to-breast volume ratios (ARR) who would otherwise be ineligible for breast conservation. METHODS: This study prospectively analyzed surgical, oncologic, and cosmetic outcomes for consecutive patients with stages 0 to III breast cancer who underwent IOUS with CWPF-based partial breast reconstruction at a single institution between 2022 and 2024. RESULTS: The study enrolled 73 female patients. The median age was 57 years, and the median tumor size was 32 mm, with 43.8% of lesions being multifocal/multicentric. The median ARR was 30.2%. The flap types included lateral intercostal artery perforator (LiCAP, 53.4%), anterior intercostal artery perforator (AICAP, 8.2%), medial intercostal artery perforator (MICAP, 19.2%), lateral thoracic artery perforator (LTAP, 16.4%), and thoracodorsal artery perforator (TDAP, 2.7%). The median flap volume was 90 cm CONCLUSIONS: The combination of IOUS and CWPFs yielded favorable surgical, cosmetic, and short-term oncologic outcome. This approach effectively and safely expands the indications for breast conservation, avoiding mastectomies, particularly for patients with small-to-medium breasts and an unfavorable ARR.
2. Recombinant Pure PDGF Improves Aesthetic Results and Patient Satisfaction Following RF Microneedling: A Prospective, Randomized, Controlled Clinical Trial.
In an evaluator-blinded randomized controlled trial, topical pure PDGF after a single RF microneedling session improved CGAIS at 7 and 30 days, outperformed standard care in 6 of 7 image analysis parameters, and yielded better patient-reported outcomes without serious adverse events.
Impact: Provides randomized evidence supporting a growth factor–based adjunct to enhance outcomes and recovery after aesthetic procedures.
Clinical Implications: Consider topical pure PDGF as an adjunct after RF microneedling to improve short-term aesthetic outcomes and patient experience; standardize dosing and application protocols while monitoring for rare adverse effects.
Key Findings
- Evaluator-blinded RCT comparing topical pure PDGF versus standard care (Aquaphor) after single RF microneedling.
- Pure PDGF improved CGAIS at 7 and 30 days and outperformed standard care in 6 of 7 Canfield image analysis parameters.
- Patient-reported outcomes favored PDGF; no serious adverse events were observed.
Methodological Strengths
- Prospective randomized controlled design with evaluator blinding.
- Use of objective image analysis (Canfield IA) and patient-reported outcomes.
Limitations
- Sample size and demographics not specified in the abstract; single-session, short 30-day follow-up.
- Single-center setting and lack of trial registration/reporting details may limit generalizability.
Future Directions: Larger, multi-center, pre-registered RCTs with longer follow-up, dose–response exploration, inclusion of diverse skin types, and head-to-head comparisons with other post-procedure adjuncts.
BACKGROUND: Platelet-Derived Growth Factor BB (PDGF) is a potent stimulator of tissue regeneration. It has received FDA approvals in four medical therapeutic indications for tissue regeneration. Recently, the use of pure PDGF has also been introduced for the promotion of skin rejuvenation and regeneration in aesthetic indications. AIMS: Evaluate the efficacy and safety of the topical application of pure PDGF compared to standard of care following radiofrequency (RF) microneedling. METHODS: In this evaluator-blinded, prospective, randomized, controlled clinical trial, subjects between 30 and 60 years of age received a single treatment of RF microneedling, followed by application of either standard of care (Aquaphor) or pure PDGF. Participants were evaluated at 7 and 30 days post-procedure by a board-certified dermatologist (MG) to determine the Clinical Global Aesthetic Improvement Score (CGAIS), and by Canfield Image Analysis (IA) software to assess seven aesthetic parameters. Patient-reported outcome measures (PROMs) were also obtained at 7 and 30 days following treatment. RESULTS: Pure PDGF treatment resulted in greater improvement in the CGAIS as determined at 7 and 30 days compared to the standard of care group. Additionally, PDGF treatment outperformed the standard of care group in 6 of 7 outcomes in the objective image analysis. PROMs indicated that participants treated with pure PDGF had an overall better experience than participants receiving standard of care. No serious adverse effects were reported. CONCLUSIONS: This prospective, randomized, controlled clinical trial shows the application of pure PDGF possesses an excellent safety profile and improves facial skin quality 30 days post RF microneedling more effectively than the current standard of care.
3. Enhanced Skin Permeation and Pigmentation Reduction Effects of a Novel Tranexamic Acid-Mandelic Acid Ion-Pairing Complex.
A spectroscopically confirmed TXA–MA ion-pairing complex increased skin permeation in Franz cell assays, suppressed UVB-induced inflammatory gene expression in HaCaT cells, and reduced pigmentation more effectively than TXA in a human in vivo assessment.
Impact: Demonstrates a formulation strategy that materially improves delivery and efficacy of a widely used depigmenting agent, with translational evidence.
Clinical Implications: The TXA–MA complex could serve as a next-generation depigmenting ingredient with improved penetration and anti-inflammatory effects; further clinical trials are needed to define dosing, safety, and benefits across skin types.
Key Findings
- Spectroscopic and zeta potential analyses confirmed formation of the TXA–MA ion-pair complex.
- Franz cell assays with porcine skin showed enhanced skin permeation versus TXA alone.
- In HaCaT cells, the complex reduced UVB-induced expression of IL-1α, IL-6, IL-8, and COX2.
- Human in vivo assessment demonstrated greater pigmentation reduction compared with TXA.
Methodological Strengths
- Multi-tier evaluation spanning physicochemical characterization, in vitro permeation, cellular assays, and human in vivo assessment.
- Use of standardized Franz cell diffusion system and defined inflammatory gene endpoints.
Limitations
- Human study design details (sample size, randomization/blinding, duration) are not reported in the abstract.
- Safety and tolerability data are not detailed; long-term efficacy remains unknown.
Future Directions: Conduct well-powered, randomized clinical trials comparing TXA–MA versus TXA and standard depigmenting agents across diverse skin types, with long-term safety and objective colorimetry outcomes.
PURPOSE: This study investigated the enhanced skin permeation and pigmentation reduction effects of an ion-pair complex formed between tranexamic acid (TXA) and mandelic acid (MA). The TXA-MA complex demonstrated superior skin permeability and greater inhibition of cytokine expression compared to TXA alone, ultimately proving more effective in reducing skin pigmentation. METHODS: After spectroscopic analysis of the TXA-MA ion-pairing complex (TXA-MA complex) structure, an in vitro skin permeation study was conducted using a Franz cell system with porcine skin. Additionally, the effect of the TXA-MA complex on UVB (ultraviolet B)-induced expression changes of inflammation-related genes (IL-1α, IL-6, IL-8, COX2) was evaluated using a human epidermal keratinocyte cell lines (HaCaT) cell model. Finally, an in vivo human study was performed to analyze the efficacy of TXA-MA in reducing actual skin pigmentation. RESULTS: The formation of the TXA-MA complex was confirmed through zeta-potential measurements, CONCLUSION: This study successfully formed a TXA-MA complex. Compared to TXA, the TXA-MA complex showed superior effects in skin permeability, inhibition of inflammatory marker expression, and actual skin pigmentation reduction. These results suggest that the TXA-MA complex holds greater potential as an effective cosmetic ingredient for pigmentation improvement than TXA alone.